Akanksha Baharani, PhD
Medical Science Liaison at Roche Diagnostics
This presentation is on Alzheimer's Disease (AD) patient journey and Diagnostics. It addresses the changes associated with the disease and the cost burden on the medicare system. Emphasis will be given on the biomarkers associated with AD, namely Abeta and Tau, and their role in the manifestation of the disease. These biomarkers become abnormal 10-15 years before the appearance of clinical symptoms. They can be detected using our Elecsys CSF assays, which can be run on Roche fully automated cobas platform.
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.
You are now leaving the website of Hoffmann-La Roche Ltd. ("Roche Canada"). Links to all external sites are provided as a resource to our visitors. Roche Canada assumes no responsibility for the content of these sites. Roche Canada has no control over these sites and the opinions, claims or comments contained in these sites should not be attributed to Roche Canada, unless otherwise specified.